Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function.
Dendritic cells (DC) are potent antigen-presenting cells (APC). Ongoing preclinical and clinical studies exploit this capacity for the immunotherapy of tumors. We tested vaccinia virus (VV) as a vector to transduce human DC. Immature and mature DC were prepared from blood monocytes and infected with (1) recombinant VV expressing GFP to analyze infection rates, virus replication in DC and the effect of infection on DC phenotype and (2) recombinant VV expressing beta-galactosidase (betaGAL) under the control of viral early, intermediate and late promoters to analyze the poxvirusdriven gene expression. While the infection rate in DC was comparable to a permissive fibroblast cell line, viral betaGAL gene expression was limited to early promoters. Genes under the control of virus late promoters were not expressed by VV in DC, indicating an abortive infection. VV infection selectively reduced the surface expression of the costimulatory molecule CD80 and the DC maturation marker CD83 on mature DC while other surface molecules including CD86 and MHC remained unchanged. In line with this finding, there was a pronounced reduction in the capacity of VV-infected DC to stimulate allogeneic or autologous T cells in mixed lymphocyte reactions. Furthermore, VV infection inhibited the maturation of immature DC after exposure to proinflammatory cytokines. These results indicate that VV-derived vectors may have complex effects on their target cells. In the case of DC used for immunotherapy, this may be detrimental to their function as potent APC and particularly their capacity to activate T helper cells.
Jenne
L
L
Department of Dermatology, University of Erlangen-Nürnberg, Germany.
Hauser
C
C
Arrighi
J F
JF
Saurat
J H
JH
Hügin
A W
AW
D017951:Antigen Presentation; D015703:Antigens, CD; D018122:B7-1 Antigen / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology*; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage*; D049452:Green Fluorescent Proteins; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology; D007167:Immunotherapy; D008164:Luminescent Proteins / Q000235:genetics; D008213:Lymphocyte Activation; D007959:Lymphocyte Culture Test, Mixed; D008562:Membrane Glycoproteins / Q000276:immunology; D011401:Promoter Regions, Genetic; D014162:Transfection / Q000379:methods*; D014616:Vaccinia virus / Q000235:genetics*; D001616:beta-Galactosidase / Q000235:genetics; D000097802:CD83 Antigen
D015703:Antigens, CD; D018122:B7-1 Antigen; D049452:Green Fluorescent Proteins; D007136:Immunoglobulins; D008164:Luminescent Proteins; D008562:Membrane Glycoproteins; D001616:beta-Galactosidase; D000097802:CD83 Antigen